ArticlesArchiveAboutEditorial BoardAuthor Guidelines
Call for papersThe 2026 special issue on Climate & Health is open for submissions.Learn more
JCT is an international journal dedicated to the latest advancements in cancer therapy. The goal of this journal is to provide a platform for doctors and academicians all over the world to promote, share, and discuss various new issues and developments in cancer related problems. All manuscripts must be prepared in En…
Manal Azizi, Abdeladim Babakhouya, Maria Rkain, Noufissa Benajiba
Rhabdomyosarcoma is a rare and aggressive mesenchymal tumor, whose paratesticular location is the most common genitourinary site. It is the preroga tive of the child and the young adult. On physical examination, a painless scrotal tumefaction is observed. His…
Hanna Sallinen, Vivi Rintanen, Leea Keski-Nisula, Maarit Anttila
Aim: Despite recent advances in the treatment of ovarian cancer, recurrence of the disease is still frequent. This study evaluated whether multiple lines of chemotherapy have impact on overall survival (OS), progression free survival (PFS) or on treatment fre…
Qi Liu, Xiang Rao, Haixiang Cai, Juncheng Guo
In this study, tumor microenvironment and related pathways play an important role in the EMT process of bile duct tumors to analyze the role of EMT in the occurrence and development of cholangiolithiasis associated bile duct carcinoma and investigate the expr…
Samia M. O’Bryan, J. Michael Mathis
Breast cancer is the most frequently diagnosed cancer in women under 60, and the second most diagnosed cancer in women over 60. While significant progress has been made in developing targeted therapies for breast cancer, advanced breast cancer continues to ha…
Kanta Ka, Papa Macoumba Gaye, Awa Sadikh Badiane, Ibrahima Thiam, Mouhamadou Bachir Ba, Papa Massamba Diene, Maimouna Mané, Lamine Niang, Fatou Samba Ndiaye
Background: The therapeutic standard for oligoprogressive prostate cancer resistant to castration is second-generation hormone therapy. This systemic treatment is expensive. There are oligoprogressive lesions accessible to radiotherapy. Objectives: To study t…
Tagne Simo Richard, Mohamadou Ahmadou, Nwabo Kamdje Armel Hervé, Seke Etet Paul Faustin, Baiguerel Erika Myriam, Danki Sillong Franklin, Telefo Phelix Bruno
Background: The incidence of prostate cancer in Cameroon has been in creasing in an alarming rate. The aim of this study is to characterize the form of prostate cancer and associated factors in patients from Cameroon Northern Regions. Methods: All patients wi…
Ibrahima Thiam, Kanta Ka, Awa Sadikh Badiane, Mouhamadou Bachir Bâ, El Hadj Amadou Sall, Boucar Ndong, Papa Ahmet Fall, Mamadou Moustapha Dieng, Papa Macoumba Gaye
Context: Technological advances have improved the toxicities of radiotherapy. We are evaluating the 3D technique in prostate cancer. Materials and Methods: Retrospective study from January 2015 to December 2015 with 29 files. Survival was calculated by Kaplan…
Guy N’da, Amine Lachgar, Oswald Houessou, Sanae El Majjaoui, Hanane El Kacemi, Tayeb Kebdani, Nourredine Benjaafar
Background and Purpose: Paragangliomas are rare tumors of the head and neck. Their management remains problematic and varies considerably de pending on the center. This study reported 14 years of experience in the management of head and neck paraganglioma (HN…
Xinle Ren, Di Zhu, Hen Wang, Jilin Wang, Biyun Lin, Yongfang Ou, Bing Huang, Jian Huang
Thyroid squamous cell carcinoma is very rare. At present, it is limited to case reports. Since the thyroid follicular epithelium is the non-squamous epithelium, how primary squamous cell carcinoma (SCC) of the thyroid occurs is still a controversial issue. Ha…
Di Zhu, Xinle Ren, Yi Luo, Bing Huang, Jian Huang
Background : Malignant granular cell tumor (GCT) is extremely rare. Malignant GCT with EP300 gene mutation in the bladder has not been reported in the literature. Case Presentation : We report a special case of 45-year-old female with malignant GCT of the bla…
No articles in this issue.
JCT is an international journal dedicated to the latest advancements in cancer therapy. The goal of this journal is to provide a platform for doctors and academicians all over the world to promote, share, and discuss various new issues and developments in cancer related problems. All manuscripts must be prepared in En… All articles are open access under a CC BY 4.0 licence, with authors retaining copyright.
Authors submit their manuscript, metadata, and declarations through the portal. There is no submission fee.
The editorial office screens the manuscript for scope, completeness, and formatting before assigning a handling editor.
At least two independent reviewers evaluate the manuscript under single-blind review. Where revisions are required, authors respond point by point.
On acceptance the article processing charge is invoiced and the CC BY 4.0 copyright handover is signed.
The article is copyedited, typeset, and given a DOI, then publishes open access with a permanent link.
Manuscripts must be original and not under consideration elsewhere. Submit in Microsoft Word or LaTeX with figures at 300 dpi minimum. Structure research articles as Abstract, Introduction, Methods, Results, Discussion, and References.
Use the journal's numbered (Vancouver) reference style. Cite sources consecutively in the order they appear, and ensure every reference is complete and retrievable.
Declare all funding sources, conflicts of interest, and ethical approvals (including informed consent and animal-care statements where applicable).